NBNeda Behzadnia

Neda Behzadnia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Neda Behzadnia has a total of 146 co-authors. Here are the top co-authors by number of shared publications:

  • Babak Sharif-Kashani

    Tobacco Prevention and Control Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

    26 shared publications
  • Zargham Hossein Ahmadi

    Lung Transplantation Research Center (LTRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

    9 shared publications
  • Mohammad Reza Masjedi

    Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    8 shared publications
  • Behnood Bikdeli

    Department of Cardiovascular Diseases, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

    7 shared publications
  • Leila Saliminejad

    Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran

    6 shared publications
  • Seyed Mohsen Mirhosseini

    Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    6 shared publications

Latest Publications

  • Superior vena cava obstruction and pulmonary artery involvement as rare findings of immunoglobulin G4-related disease

    by Neda Behzadnia, Faezeh Sheybani-Afshar, Babak Sharif-Kashani, Zargham-Hossein Ahmadi, Mihan Pourabdollah

  • Open Access

    A novel mutation in PRKAR1A gene in a patient with Carney complex presenting with pituitary macroadenoma, acromegaly, Cushing's syndrome and recurrent atrial myxoma

    by Ali A. Ghazi, Mohammad Hossein Mandegar, Mohammad Abazari, Neda Behzadnia, Taraneh Sadeghian, Siamak Shariat Torbaghan, Alireza Amirbaigloo

    Carney complex (CNC) is a rare syndrome of multiple endocrine and non-endocrine tumors. In this paper we present a 23-year-old Iranian woman with CNC who harbored a novel mutation (c.642dupT) in PRKAR1A gene. This patient presented with pituitary macroadenoma, acromegaly, recurrent atrial myxoma, Cushing's syndrome secondary to primary pigmented nodular adrenocortical disease and pigmented schwanoma of the skin. PRKAR1A gene was PCR amplified using genomic DNA and analyzed for sequence variants which revealed the novel mutation resulting in substitution of amino acid cysteine instead of the naturally occurring valine in the peptide chain and a premature stop codon at position 18 (V215CfsX18). This change leads to development of tumors in different organs due to lack of tumor suppressive activity secondary to failure of synthesis of the related protein.


    • 1 October 2018
      • Vol. 17  (4) , 295-298
    Open Access

    Traumatic Transection of Descending Thoracic Aorta Presenting as Pseudo- Coarctation

    by Shadi Shafaghi, Neda Behzadnia, Babak Sharif-Kashani, Farah Naghashzadeh, Zargham Hossein Ahmadi

    Background: Thoracic Aortic Injury (TAI) due to penetrating or blunt chest trauma is a critical life-threatening aortic injury. Its diagnosis and treatment always is challenging.

    • 1 May 2018
      • Vol. 12  (3) , 185-189

    Blood Pressure Measurement and Left Ventricular Mass Index in Hemodialysis Patients Comparison of Several Methods

    by Amir Ahamd Nassiri, Legha Lotfollahi, Neda Behzadnia, Ilad Alavi Darazam, Monir Sadat Hakemi, Azam Rahimzadeh Kalaleh, Mina Kamalkhani

    Introduction. Systemic arterial hypertension is prevalent in endstage renal disease and is closely associated with left ventricular hypertrophy (LVH). Blood pressure (BP) behavior is unique in this population, and it is not clear which BP measurement should be used for treatment guidance. We aimed to evaluate the association of several methods of BP measurement with left ventricular mass index (LVMI) as hypertensive end-organ damage. Materials and Methods. Patients on maintenance hemodialysis, 3 or 4 times per week for at least 3 months, were enrolled. We compared the diagnostic value of 6 different methods of BP measurement, including predialysis, postdialysis, interdialysis, and standard BP measurements as well as ambulatory blood pressure monitoring (ABPM) and home blood pressure monitoring, based on LVMI as the gold standard. Results. Twenty patients, including 9 women and 11 men were enrolled. Ten patients (50%) had LVH and the others had normal LVMI (LVMI > 100 g/m(2) for women and > 131 100 g/m(2) for men). Only predialysis and postdialysis systolic BP values were significantly associated with LVMI (P = .02 and P = .02, respectively). Conclusions. Predialysis and postdialysis systolic BP values maybe reliable for detecting hypertension in hemodialysis patients, although according to previous data, the importance of self and ambulatory BP monitoring could not be overlooked.


    • 1 July 2017
      • Vol. 12  (3) , 142-144
    Open Access

    Asymptomatic Giant Lipoma of the Right Ventricular Outflow Tract: A Case Report

    by Fariba Bayat, Zargham Hossein Ahmadi, Neda Behzadnia, AtosA Dorudinia, Alireza Jahangirifard

    Cardiac lipomas are extremely rare tumors of the heart. They are usually symptomatic and rarely may be found incidentally in autopsies. Here we describe a 23-year-old healthy man, in whose physical examination for employment a murmur was found incidentally. Transthoracic and then transesophageal echocardiographic examination showed a 4-cm oval-shaped mass in the right ventricular outflow tract. He underwent elective surgery, during which the tumor was removed under cardiopulmonary bypass and aortic-cross clamping via right atriotomy. The postoperative course was uneventful, and the patient was in good condition at 1 year’s follow-up.


    • 1 June 2017
      • Vol. 16  (4) , 283-288
    Open Access

    Relationship between Serum Uric Acid Levels and the Severity of Pulmonary Hypertension

    by Seyyed Reza Seyyedi, Majid Malekmohammad, Mandana Chitsazan, Neda Behzadnia, Makan Sadr, Seyed Mohammadreza Hashemian, Babak Sharif-Kashani

    Right heart catheterization is the gold standard test for diagnosis and clinical assessment of the patients with pulmonary hypertension (PH). In recent years, the usefulness of cheaper and non-invasive tests in the follow-up of PH patients is being studied. The aim of the present study was to evaluate the relationship between serum uric acid level and severity of pulmonary hypertension in PH patients. In a cross-sectional study, serum uric acid was measured in 110 patients with PH (63 women; mean age [±SD] was 52.83±17.88 years). Pulmonary arterial pressure and severity of right ventricular dysfunction were assessed using RHC and echocardiography, respectively. Serum uric acid was higher in PH patients with severe RV dysfunction, compared to mild and moderate dysfunction (7.8mg/dl [IQR: 5.8–9.2] in severe dysfunction, versus 4.7 mg/dl [3.87–5.82] in mild dysfunction and 5 mg/dl [3.5–6.95] in moderate dysfunction. Serum uric acid was significantly correlated with pulmonary artery systolic pressure (r=0.51, P<0.001). Serum uric acid level also had a significant positive correlation with the World Health Organization functional class of the patients (r=0.49, P<0.001). Serum uric acid level greater than 5.7 mg/dl was found to be the most sensitive and specific points for predicting severe RV dysfunction in PH patients (sensitivity 76.6%, specificity 71.4%; AUC=0.79, P<0.001) . Serum uric acid is correlated with the severity of symptoms and RV dysfunction in patients with pulmonary hypertension. Further studies are recommended with larger sample size in this regard.


  • Smoking and wound complications after coronary artery bypass grafting

    by Babak Sharif-Kashani, Payman Shahabi, Mohammad-Hossein Mandegar, Leila Saliminejad, Behnood Bikdeli, Neda Behzadnia, Gholamreza Heydari, Hooman Sharifi, Savalan Aidanlou


    • 1 January 2016
      • Vol. 15  (2) , 117-120
    Open Access

    Treatment of Recurrent Prosthetic Mitral Valve Thrombosis with Reteplase: A Report of Four Cases

    by Neda Behzadnia, Babak Sharif Kashani, Arda Kiani, Atefe Abedini, Seyed Reza Seyedi, Hossein Zargham Ahmadi, Farah Naghash Zadeh, Atefeh Fakharian

    Thrombosis is a life threatening complications of prosthetic mitral valves and is associated with high morbidity and mortality. Even in presence of systemic anticoagulation prosthetic valve thrombosis has an incidence of 0.5% to 8%. Recurrent prosthetic valve thrombosis and the resulting thrombotic occlusion require re-establishment of blood flow across the valve. While surgical repair is considered the classic first line treatment option for prosthetic valve thrombosis, intravenous thrombolysis has emerged as an acceptable alternative for the first episode of prosthetic valve thrombosis. Due to the limitation of using streptokinase in recurrent thrombotic events, fibrin-specific tissue plasminogen activators have been successfully utilized to treat cases of recurrent prosthetic valve thrombosis. In this case-series, we have reported four cases of recurrent prosthetic valve thrombosis that were successfully treated with Reteplase at our hospital.


  • Asymptomatic Mycotic Aneurysm of Ascending Aorta After Heart Transplantation: A Case Report

    by N. Behzadnia, Z.H. Ahmadi, M.H. Mandegar, F. Salehi, B. Sharif-Kashani, M. Pourabdollah, Z. Ansari-Aval, A.-A. Kianfar, S.M. Mirhosseini, M. Eiji


  • Hemodynamic and symptomatic improvement after delayed thrombolysis with Reteplase in a patient with massive bilateral pulmonary emboli

    by Babak Sharif-Kashani, Arda Kiani, Mehrdad Bakhshayesh-Karam, Faezeh Sheybani-Afshar, Neda Behzadnia, Farah Naghash-Zadeh

    Most patients surviving the acute phase of pulmonary embolism will recover with no residue. But, 2-4% of patients will progress to chronic thromboembolic pulmonary hypertension. In this group, usually a 'Honey moon' period is seen but a few may show progression with ongoing symptoms despite medical treatment. In this case report, we review a patient in whom delayed thrombolytic therapy was administered due to progressive symptoms after 21 days. Her condition was stabilized. The early posttreatment computed tomographic pulmonary angiography (CTPA) showed incomplete resolution, but after 6 months she was functional class I with a normal CTPA and echocardiography.